Excellthera Inc.
Clinical trials sponsored by Excellthera Inc., explained in plain language.
-
Expanded cord blood transplant shows early promise for young cancer patients
Disease control CompletedThis study tested a new method of cord blood transplantation in 13 children and young adults with high-risk myeloid cancers. The approach uses a molecule called UM171 to grow more stem cells from a single cord blood unit, aiming to speed up recovery and reduce complications. Earl…
Phase: PHASE1, PHASE2 • Sponsor: ExCellThera inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Cord blood boost: new technique shows promise for tough leukemia cases
Disease control CompletedThis study tested a new way to prepare cord blood for transplant in 30 people with high-risk leukemia or myelodysplasia. The cord blood was treated with a molecule called UM171 to help it grow more stem cells. The goal was to see if this approach is safe and helps patients recove…
Phase: PHASE2 • Sponsor: ExCellThera inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC